MedTrace Logo

Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis

NCT01066364 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2020-07-21

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to see if the drug colesevelam is a potential treatment for Nonalcoholic Steatohepatitis(NASH).

Conditions

Interventions

DRUG

Colesevelam Hcl

3.75 gm/day (six 675 mg tablets)

Sponsors & Collaborators

Principal Investigators

  • Rohit Loomba, MD, M.H.Sc · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01066364 on ClinicalTrials.gov